Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728780 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.
A Phase 1 study of Adverse Events and Pharmacokinetic Variables, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00728780: Completed Phase 1 study of Adverse Events and Pharmacokinetic Variables, sponsored by AstraZeneca.
NCT00728780 is a Phase 1 study of Adverse Events and Pharmacokinetic Variables that has completed, run by AstraZeneca. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728780, a Phase 1 study of Adverse Events and Pharmacokinetic Variables, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
Conditions Studied
Interventions
- DRUG ABT-143
- DRUG ABT-335 and rosuvastatin
Study Locations (1)
Indiana
- Site Reference ID/Investigator# 11101 - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-08 |
| Phase | Phase 1 |
What the finished NCT00728780 record still lists
NCT00728780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 2 conditions, with Adverse Events appearing as the primary indexed condition, and to 2 interventions - of which ABT-143 is the first listed.
NCT00728780 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00728780 about?
NCT00728780 is a clinical study titled "Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.". The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.
What is the current status of trial NCT00728780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-08.
What conditions does trial NCT00728780 study?
This clinical trial studies the following conditions: Adverse Events, Pharmacokinetic Variables.
What interventions are being tested in trial NCT00728780?
The interventions under investigation include: ABT-143 (DRUG), ABT-335 and rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00728780?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00728780 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Events
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00728780's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia